Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Promethazin (ausschl. Dafo. TEI), ATC N05CM22 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)

Section 130a (8) of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount agreements on medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB). For pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Promethazin (exclusively in the form of TEI), ATC N05CM22, the DAK-Gesundheit intends to conclude pharmaceutical discount agreements with as many interested pharmaceutical companies as possible until new pharmaceutical discount agreements come into force. A discount agreement for the aforementioned substance under the licensing model comes into force for the first time on 01.07.2026 and ends on 30.06.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.